<DOC>
	<DOCNO>NCT00228917</DOCNO>
	<brief_summary>This study conduct two stage . In diphtheria , tetanus , pertussis ( DTP ) booster phase , subject receive booster dose Tritanrix™-HepB/Hib-MenAC Tritanrix™-HepB/Hiberix™ ( active control ) 15 18 24 month single-blind manner subject ' parent know vaccine administer child . In Mencevax ACWY phase 24-30 month , dose Mencevax™ ACWY give open manner subject receive less 4 dos Tritanrix™-HepB/Hib-MenAC . No blood sample take safety study .</brief_summary>
	<brief_title>Safety Study Tritanrix™-HepB/Hib-MenAC , Tritanrix™-HepB/Hiberix™ , Mencevax™ ACWY Vaccines Children</brief_title>
	<detailed_description>Subjects previously prim Tritanrix™-HepB/Hib-MenAC receive Tritanrix™-HepB/Hib-MenAC Tritanrix™-HepB/Hiberix™ vaccine ( 15-18/24 ) , respectively , without Mencevax™ ACWY vaccine 24 30 month age . Subjects previously prim Tritanrix™-HepB/Hiberix™ receive Tritanrix™-HepB/Hib-MenAC Tritanrix™-HepB/Hiberix™ vaccine ( 15-18/24 ) Mencevax™ ACWY vaccine 24 30 month age .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent obtain parent guardian healthy male female child , include 15 18 month age ( Philippines ) / 15 24 month age ( Thailand ) time vaccination previously receive 3dose primary vaccination study DTPwHB/HibMenACTT004 ( CPMS No . 759346/004 ) DTPWHBV=HIBMENACTT013 ( eTrack No . 100791 ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede vaccination , plan use study period . Chronic administration ( &gt; 14 day ) immunosuppressant immunemodifying drug within six month prior vaccination . Planned administration/administration vaccine foreseen study protocol within 30 day vaccination . Note : Oral poliovirus vaccine give concomitantly . Booster vaccination diphtheria , tetanus , pertussis , hepatitis B , Haemophilus influenzae type b ( Hib ) and/or meningococcal serogroups A C disease , date study conclusion visit primary vaccination study .</criteria>
	<gender>All</gender>
	<minimum_age>427 Days</minimum_age>
	<maximum_age>577 Days</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hib &amp; Neisseria meningitidis serogroups A &amp; C disease</keyword>
</DOC>